- 全部删除
- 您的购物车当前为空
RP-1664(化合物 RP-1664) 是一种口服有效的选择性 PLK4 抑制剂,IC50值为3 nM,在乳腺癌和神经母细胞瘤研究中显示抗肿瘤活性。
RP-1664(化合物 RP-1664) 是一种口服有效的选择性 PLK4 抑制剂,IC50值为3 nM,在乳腺癌和神经母细胞瘤研究中显示抗肿瘤活性。
RP-1664 相关产品
产品描述 | RP-1664 is a selective and orally active PLK4 inhibitor with an IC50 of 3 nM. This compound demonstrates exceptional selectivity over related kinases, disrupts centriole biogenesis in cancer cells leading to PLK4 and p21 protein accumulation, shows enhanced sensitivity in TRIM37-high-expressing cells, and exhibits antitumor activity in breast cancer and neuroblastoma research. |
体外活性 | 方法:RP-1664(1-1000 nM,48-72小时)处理RPE1-hTERT Cas9 TP53 基因敲除细胞和 RPE1-hTERT Cas9 TP53 野生型细胞,Western Blot 分析目标蛋白的表达情况。 |
别名 | RP1664 |
分子量 | 514.55 |
分子式 | C23H24F2N8O2S |
CAS No. | 2980682-00-4 |
Smiles | O=S(=O)(C1=CC(F)=C(C(F)=C1)N(C=2N=C(NC3=NNC(=C3)C)C(=C(N2)C=4N=CN(C4)C)C5CC5)C)C |
密度 | no data available |
存储 | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 80 mg/mL (155.48 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容